Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01386723 · ClinicalTrials.gov registry record
End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- 35
- Enrollment target
NCT01386723 is a clinical trial that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 35 participants.
The verdict
NCT01386723 was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- 35 participants
- Enrollment target
Study Summary
This study proposes to observe whether a stable platelet count would be maintained without additional treatment in the long term in at least a proportion of patients who have discontinued eltrombopag taken for at least 4 months. This requires that if patients stop treatment with eltrombopag, they are not immediately transitioned to further treatment unless it is necessary. The objective of the study is to assess how frequently patients who have discontinued eltrombopag attain a stable, treatment-free, unmaintained adequate platelet count 4 to 8 weeks after discontinuing eltrombopag and how long such a response lasts (if it occurs).
Interventions
- DRUG Discontinuation of eltrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01386723
The ClinicalTrials.gov registry entry for NCT01386723 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Discontinuation of eltrombopag is the first listed.
NCT01386723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01386723 about?
NCT01386723 is a clinical study titled "End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia". This study proposes to observe whether a stable platelet count would be maintained without additional treatment in the long term in at least a proportion of patients who have discontinued eltrombopag taken for at least 4 months. This requires that if patients stop treatment with eltrombopag, they ar...
What is the current status of trial NCT01386723?
This trial is currently terminated. The enrollment target is 35 participants. The study started on 2011-06.
What interventions are being tested in trial NCT01386723?
The interventions under investigation include: Discontinuation of eltrombopag (DRUG).
Who is sponsoring clinical trial NCT01386723?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.